Skip to main content

Table 4 Viral nucleic acid negative-converting rate within 14 days and not negative rate at last assay in patients with or without Arbidol based on gender, age and maximum body temperature

From: Clinical features and efficacy of antiviral drug, Arbidol in 220 nonemergency COVID‐19 patients from East-West-Lake Shelter Hospital in Wuhan: a retrospective case series

Male

Without Arbidol (n = 39)

With Arbidol (n = 58)

p value

OR (95% CI)

Time to PCR negative in respiratory specimens

 ≤ 14 days (%)

19 (48.7)

45 (77.6)

0.005*

0.27 (0.11, 0.66)

 > 14 days (%)

20 (51.3)

13 (22.4)

0.005*

 

 Not negative (%)

9 (23.1)

2 (3.4)

0.006*

8.40 (1.70, 41.42)

Female

Without Arbidol (n = 24)

With Arbidol (n = 41)

p value

OR (95% CI)

≤ 14 days (%)

16 (66.7)

27 (65.9)

1

 

> 14 days (%)

8 (33.3)

14 (34.1)

1

 

Not negative (%)

0 (0.00)

3 (7.3)

0.55

 

≤ 50 years

Without Arbidol (n = 30)

With Arbidol (n = 59)

p value

OR (95% CI)

≤ 14 days (%)

16 (53.3)

43 (72.9)

0.096

 

> 14 days (%)

14 (46.7)

16 (27.1)

0.096

 

Not negative (%)

4 (13.3)

3 (5.1)

0.22

 

> 50 years

Without Arbidol (n = 33)

With Arbidol (n = 40)

p value

OR (95% CI)

≤ 14 days (%)

19 (57.6)

28 (70.0)

0.33

 

> 14 days (%)

14 (42.4)

12 (30.3)

0.33

 

Not negative (%)

5 (15.2)

2 (5.0)

0.23

 

≤ 38.5 C

Without Arbidol (n = 42)

With Arbidol (n = 67)

p value

OR (95% CI)

 ≤ 14 days (%)

24 (57.1)

47 (70.1)

0.22

 

 > 14 days (%)

18 (42.9)

20 (29.9)

0.22

 

Not negative (%)

6 (14.3)

4 (6.0)

0.18

 

> 38.5C

Without Arbidol (n = 21)

With Arbidol (n = 32)

p value

OR (95% CI)

≤ 14 days (%)

11 (52.4)

25 (78.1)

0.07

 

> 14 days (%)

10 (47.6)

7 (21.9)

0.07

 

Not negative (%)

3 (14.3)

1 (3.1)

0.29

 
  1. *Statistically significant p vaues